{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:19:43Z","timestamp":1790623183664,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["HHSN272200800051C"],"award-info":[{"award-number":["HHSN272200800051C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["HHSN272201000035C"],"award-info":[{"award-number":["HHSN272201000035C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.07.076","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T12:30:16Z","timestamp":1501504216000},"page":"4952-4959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate"],"prefix":"10.1016","volume":"35","author":[{"given":"Vladimir","family":"Savransky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry D.","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melicia R.","family":"Gainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Sivko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory V.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Ionin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2017.07.076_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.076_b0010","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.00090-06","article-title":"Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model","volume":"50","author":"Kao","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.076_b0015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.076_b0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/14760584.2016.1254556","article-title":"Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule","volume":"15","author":"Longstreth","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.076_b0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"30","key":"10.1016\/j.vaccine.2017.07.076_b0030","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2017.07.076_b0035","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","article-title":"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults","volume":"34","author":"Hopkins","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.076_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14760584.5.3.365","article-title":"CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine","volume":"5","author":"Klinman","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"14","key":"10.1016\/j.vaccine.2017.07.076_b0045","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.vaccine.2005.12.034","article-title":"Enhancement of functional antibody responses to AMA1-C1\/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide","volume":"24","author":"Mullen","year":"2006","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2017.07.076_b0050","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.076_b0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.076_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0966-842X(96)81515-0","article-title":"Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA","volume":"4","author":"Krieg","year":"1996","journal-title":"Trends Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.076_b0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)80256-3","article-title":"Immune activation by bacterial DNA: a new genetic code","volume":"5","author":"Pisetsky","year":"1996","journal-title":"Immunity"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2017.07.076_b0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0264-410X(99)00316-3","article-title":"Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines","volume":"18","author":"Kim","year":"1999","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.076_b0075","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.076_b0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.coviro.2012.01.004","article-title":"Licensure of vaccines using the Animal Rule","volume":"2","author":"Burns","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2017.07.076_b0085","unstructured":"Guidance for Industry Animal Models \u2014 Essential Elements to Address Efficacy Under the Animal Rule [Internet]. 2015. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM399217.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.076_b0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/MMBR.68.4.617-629.2004","article-title":"Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines","volume":"68","author":"Phipps","year":"2004","journal-title":"Microbiol Mol Biol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.076_b0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mam.2009.07.005","article-title":"Animal models of human anthrax: the Quest for the Holy Grail","volume":"30","author":"Goossens","year":"2009","journal-title":"Mol Aspects Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.076_b0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/108729001753231713","article-title":"CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved","volume":"11","author":"Rankin","year":"2001","journal-title":"Antisense Nucl Acid Drug Dev"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.076_b0105","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1128\/IAI.01289-12","article-title":"Pathology and pathophysiology of inhalational anthrax in a guinea pig model","volume":"81","author":"Savransky","year":"2013","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.076_b0110","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.076_b0115","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.LAB.0000080599.43791.01","article-title":"Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis)","volume":"83","author":"Vasconcelos","year":"2003","journal-title":"Lab Invest"},{"issue":"32","key":"10.1016\/j.vaccine.2017.07.076_b0120","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2017.07.076_b0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2017.07.076_b0130","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","author":"Little","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.076_b0135","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.07.076_b0140","doi-asserted-by":"crossref","unstructured":"M.P. Fay, D.A. Follmann, F. Lynn, J.M. Schiffer, G.V. Stark, R. Kohberger, et al. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med 4(151) (2012):151ra26.","DOI":"10.1126\/scitranslmed.3004073"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.076_b0145","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.076_b0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals","volume":"150","author":"Guyton","year":"1947","journal-title":"Am J Physiol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2017.07.076_b0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.076_b0160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.076_b0165","doi-asserted-by":"crossref","unstructured":"D. Hering, W. Thompson, J. Hewetson, S. Little, S. Norris, J. Pace-Templeton, Validation of the anthrax lethal toxin neutralization assay, Biol: J Int Assoc Biol Standard 2004;32(1):17\u201327.","DOI":"10.1016\/j.biologicals.2003.09.003"},{"key":"10.1016\/j.vaccine.2017.07.076_b0170","unstructured":"Agents CoAMfACtB. Animal Models for Assessing Countermeasures to Bioterrorism Agents In: Institute for Laboratory Animal Research DoEaLS, National Research Council, editor. Washington DC: National Academies Press; 2011. p. 116."},{"key":"10.1016\/j.vaccine.2017.07.076_b0175","series-title":"vaccines","first-page":"14","article-title":"2 - Vaccine immunology A2 \u2013 Plotkin, Stanley A","author":"Siegrist","year":"2013"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.076_b0180","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/IAI.72.6.3471-3477.2004","article-title":"Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine","volume":"72","author":"Marcus","year":"2004","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.076_b0185","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.181.8.5785","article-title":"Effect of CpG oligonucleotides on vaccine-induced B cell memory","volume":"181","author":"Tross","year":"2008","journal-title":"J Immunol"},{"issue":"50","key":"10.1016\/j.vaccine.2017.07.076_b0190","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.vaccine.2014.01.096","article-title":"Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)","volume":"32","author":"Minang","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T20:56:35Z","timestamp":1569963395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17310022"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}